247 related articles for article (PubMed ID: 17467893)
21. Chromosome 3p tumor-suppressor gene alterations in cervical carcinomas.
Herzog CR; Crist KA; Sabourin CL; Kelloff GJ; Boone CW; Stoner GD; You M
Mol Carcinog; 2001 Mar; 30(3):159-68. PubMed ID: 11301476
[TBL] [Abstract][Full Text] [Related]
22. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
23. [Methylation status of FHIT gene in plasma and expression of FHIT gene in cancer tissue of cervical cancer patients].
Ren CC; Miao XH; Yang B; Zhao L; Sun R; Song WQ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Oct; 23(5):565-7. PubMed ID: 17029211
[TBL] [Abstract][Full Text] [Related]
24. [Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas].
Hong FZ; Wang B; Li HM; Liew CT
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):257-61. PubMed ID: 16181544
[TBL] [Abstract][Full Text] [Related]
25. The fragile histidine triad gene: a molecular link between cigarette smoking and cervical cancer.
Holschneider CH; Baldwin RL; Tumber K; Aoyama C; Karlan BY
Clin Cancer Res; 2005 Aug; 11(16):5756-63. PubMed ID: 16115913
[TBL] [Abstract][Full Text] [Related]
26. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y
Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865
[TBL] [Abstract][Full Text] [Related]
27. [Hypermethylation of promoter region of RAS association domain family gene1A in esophageal squamous cell carcinoma and significance thereof].
Cong DG; Wang SF
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2932-4. PubMed ID: 18261310
[TBL] [Abstract][Full Text] [Related]
28. Frequent hypermethylation of RASSF1A in early flat-type colorectal tumors.
Sakamoto N; Terai T; Ajioka Y; Abe S; Kobayasi O; Hirai S; Hino O; Watanabe H; Sato N; Shimoda T; Fujii H
Oncogene; 2004 Nov; 23(55):8900-7. PubMed ID: 15480433
[TBL] [Abstract][Full Text] [Related]
29. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
Ismail HM; Medhat AM; Karim AM; Zakhary NI
Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
[TBL] [Abstract][Full Text] [Related]
30. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
31. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma.
Scholes AG; Liloglou T; Maloney P; Hagan S; Nunn J; Hiscott P; Damato BE; Grierson I; Field JK
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2472-7. PubMed ID: 11581185
[TBL] [Abstract][Full Text] [Related]
32. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development.
Lea JS; Ashfaq R; Muneer S; Burbee DG; Miller DS; Minna JD; Muller CY
J Soc Gynecol Investig; 2004 Jul; 11(5):329-37. PubMed ID: 15219888
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
[TBL] [Abstract][Full Text] [Related]
34. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
35. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma.
Riquelme E; Tang M; Baez S; Diaz A; Pruyas M; Wistuba II; Corvalan A
Cancer Lett; 2007 May; 250(1):100-6. PubMed ID: 17084965
[TBL] [Abstract][Full Text] [Related]
36. RAR beta2 suppression in head and neck squamous cell carcinoma correlates with site, histology and age.
Olasz J; Juhász A; Remenár E; Engi H; Bak M; Csuka O; Kásler M
Oncol Rep; 2007 Jul; 18(1):105-12. PubMed ID: 17549354
[TBL] [Abstract][Full Text] [Related]
37. [Methylation of the putative tumor suppressor gene, RASSF1A, in primary cervical tumors].
Maliukova AV; Loginov VI; Khodyrev DS; Kadyrova EL; Pronina IV; Ivanova TA; Kiselev FL; Zabarovskiĭ NP; Braga EA
Mol Biol (Mosk); 2004; 38(6):1005-13. PubMed ID: 15612586
[TBL] [Abstract][Full Text] [Related]
38. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
[TBL] [Abstract][Full Text] [Related]
39. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
[TBL] [Abstract][Full Text] [Related]
40. Fhit expression is absent or reduced in a subset of primary head and neck cancer.
Götte K; Hadaczek P; Coy JF; Wirtz HW; Riedel F; Neubauer J; Hörmann K
Anticancer Res; 2000; 20(2A):1057-60. PubMed ID: 10810397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
